The Motley Fool

I think AstraZeneca shares could pay you for the rest of your life

Image source: Getty Images.

This year, UK companies have cut or deferred a staggering £30bn in dividend payouts to investors. However, several firms have bucked this trend. AstraZeneca (LSE: AZN) shares for one, still offer investors a healthy level of dividend income. 

I think the company can maintain these dividend credentials for decades. Today, I’m going to explain why. 

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

AstraZeneca shares may offer income for life 

As one of the UK’s largest healthcare companies, AstraZeneca is one of the most defensive investments on the London market. This year, AstraZeneca shares have taken off.

The company is at the forefront of the worldwide hunt for a coronavirus vaccine. If it can cross the finish line first, there could be substantial financial rewards for the business. 

But this is just one string to Astra’s bow. The company has a stable of other treatments on sale or in development that will support growth for the next few years.

For example, during the past decade, the firm has invested billions in its oncology business. These investments are now really starting to pay off. The group currently has a handful of oncology treatments on the market, which have exceeded £1bn in annual sales. These have helped improve investor sentiment towards AstraZeneca shares.

More launches are planned over the next few years, and the firm is always looking for new ways it can use its treatments to help cancer patients. 

As well as this specialist business, Astra also has a reliable income stream from its cardiovascular drugs and respiratory treatments. These complement its rapidly growing oncology business. 

The world will always need Astra’s treatments. Unfortunately, cancers and diseases are not going to vanish overnight. They’re only becoming more common as the world’s population grows and becomes older. This should provide a strong tailwind for AstraZeneca’s shares in the years and decades ahead. 

Pay you for life

As such, based on this favourable backdrop, I think AstraZeneca shares could pay you for the rest of your life. Not only is the demand for the company’s treatments and products unlikely to drop over the long term, management is also investing significant amounts to make sure the business stays ahead of the competition. It always has new products to bring to market.

I’m encouraged by this investment, and I think it could help the company’s bottom line grow steadily in the long run which should, in turn, support dividend growth.

The stock currently supports a dividend yield of 2.5%, which is below the FTSE 100 average of around 3.7%. Nevertheless, I think it’s worth taking the lower return considering the company’s long-term growth potential. What’s more, unlike so many other FTSE 100 corporations, Astra has maintained its dividend through the current crisis.

In my opinion, it’s certainly worth taking this fact into account when considering AstraZeneca shares for your portfolio. There aren’t many other businesses that offer the same kind of defensive qualities.

“This Stock Could Be Like Buying Amazon in 1997”

I'm sure you'll agree that's quite the statement from Motley Fool Co-Founder Tom Gardner.

But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.

What's more, we firmly believe there's still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.

And right now, we're giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool.

Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge!

Rupert Hargreaves owns no share mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

The renowned analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply enter your email address below to discover how you can take advantage of this.

I would like to receive emails from you about product information and offers from The Fool and its business partners. Each of these emails will provide a link to unsubscribe from future emails. More information about how The Fool collects, stores, and handles personal data is available in its Privacy Statement.